Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ

Open source

DOI
10.1038/s41523-021-00337-2
Published
2021 Oct 5
Container
NPJ breast cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41523-021-00337-2,
  title = {Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.},
  author = {Yee D and Isaacs C and Wolf DM and Yau C and Haluska P and Giridhar KV and Forero-Torres A and Jo Chien A and Wallace AM and Pusztai L and Albain KS and Ellis ED and Beckwith H and Haley BB and Elias AD and Boughey JC and Kemmer K and Yung RL and Pohlmann PR and Tripathy D and Clark AS and Han HS and Nanda R and Khan QJ and Edmiston KK and Petricoin EF and Stringer-Reasor E and Falkson CI and Majure M and Mukhtar RA and Helsten TL and Moulder SL and Robinson PA and Wulfkuhle JD and Brown-Swigart L and Buxton M and Clennell JL and Paoloni M and Sanil A and Berry S and Asare SM and Wilson A and Hirst GL and Singhrao R and Asare AL and Matthews JB and Hylton NM and DeMichele A and Melisko M and Perlmutter J and Rugo HS and Fraser Symmans W and Van't Veer LJ and Berry DA and Esserman LJ},
  year = {2021},
  journal = {NPJ breast cancer},
  doi = {10.1038/s41523-021-00337-2},
  url = {https://doi.org/10.1038/s41523-021-00337-2}
}

RIS

TY  - JOUR
TI  - Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
AU  - Yee D
AU  - Isaacs C
AU  - Wolf DM
AU  - Yau C
AU  - Haluska P
AU  - Giridhar KV
AU  - Forero-Torres A
AU  - Jo Chien A
AU  - Wallace AM
AU  - Pusztai L
AU  - Albain KS
AU  - Ellis ED
AU  - Beckwith H
AU  - Haley BB
AU  - Elias AD
AU  - Boughey JC
AU  - Kemmer K
AU  - Yung RL
AU  - Pohlmann PR
AU  - Tripathy D
AU  - Clark AS
AU  - Han HS
AU  - Nanda R
AU  - Khan QJ
AU  - Edmiston KK
AU  - Petricoin EF
AU  - Stringer-Reasor E
AU  - Falkson CI
AU  - Majure M
AU  - Mukhtar RA
AU  - Helsten TL
AU  - Moulder SL
AU  - Robinson PA
AU  - Wulfkuhle JD
AU  - Brown-Swigart L
AU  - Buxton M
AU  - Clennell JL
AU  - Paoloni M
AU  - Sanil A
AU  - Berry S
AU  - Asare SM
AU  - Wilson A
AU  - Hirst GL
AU  - Singhrao R
AU  - Asare AL
AU  - Matthews JB
AU  - Hylton NM
AU  - DeMichele A
AU  - Melisko M
AU  - Perlmutter J
AU  - Rugo HS
AU  - Fraser Symmans W
AU  - Van't Veer LJ
AU  - Berry DA
AU  - Esserman LJ
PY  - 2021
JO  - NPJ breast cancer
DO  - 10.1038/s41523-021-00337-2
UR  - https://doi.org/10.1038/s41523-021-00337-2
ER  -

APA

D, Y., C, I., DM, W., C, Y., P, H., KV, G., A, F., A, J. C., AM, W., L, P., KS, A., ED, E., H, B., BB, H., AD, E., JC, B., K, K., RL, Y., PR, P., D, T., AS, C., HS, H., R, N., QJ, K., KK, E., EF, P., E, S., CI, F., M, M., RA, M., TL, H., SL, M., PA, R., JD, W., L, B., M, B., JL, C., M, P., A, S., S, B., SM, A., A, W., GL, H., R, S., AL, A., JB, M., NM, H., A, D., M, M., J, P., HS, R., W, F. S., LJ, V. V., DA, B., & LJ, E. (2021). Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.. NPJ breast cancer. https://doi.org/10.1038/s41523-021-00337-2

Source records